It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Histological stratification in metastatic non-small cell lung cancer (NSCLC) is essential to properly guide therapy. Morphological evaluation remains the basis for subtyping and is completed by additional immunohistochemistry labelling to confirm the diagnosis, which delays molecular analysis and utilises precious sample. Therefore, we tested the capacity of convolutional neural networks (CNNs) to classify NSCLC based on pathologic HES diagnostic biopsies. The model was estimated with a learning cohort of 132 NSCLC patients and validated on an external validation cohort of 65 NSCLC patients. Based on image patches, a CNN using InceptionV3 architecture was trained and optimized to classify NSCLC between squamous and non-squamous subtypes. Accuracies of 0.99, 0.87, 0.85, 0.85 was reached in the training, validation and test sets and in the external validation cohort. At the patient level, the CNN model showed a capacity to predict the tumour histology with accuracy of 0.73 and 0.78 in the learning and external validation cohorts respectively. Selecting tumour area using virtual tissue micro-array improved prediction, with accuracy of 0.82 in the external validation cohort. This study underlines the capacity of CNN to predict NSCLC subtype with good accuracy and to be applied to small pathologic samples without annotation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Normandy University, Department of Pathology, Caen University Hospital, Caen, France (GRID:grid.460771.3) (ISNI:0000 0004 1785 9671)
2 Georges François Leclerc Cancer Center—UNICANCER, Platform of Transfer in Biological Oncology, Dijon, France (GRID:grid.460771.3)
3 Georges François Leclerc Cancer Center—UNICANCER, Platform of Transfer in Biological Oncology, Dijon, France (GRID:grid.460771.3); Dijon University Hospital, Genomic and Immunotherapy Medical Institute, Dijon, France (GRID:grid.31151.37)
4 Georges François Leclerc Cancer Center—UNICANCER, Platform of Transfer in Biological Oncology, Dijon, France (GRID:grid.31151.37); Dijon University Hospital, Genomic and Immunotherapy Medical Institute, Dijon, France (GRID:grid.31151.37); University of Burgundy-Franche Comté, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313); UMR INSERM 1231, Dijon, France (GRID:grid.5613.1)
5 Georges François Leclerc Cancer Center—UNICANCER, Platform of Transfer in Biological Oncology, Dijon, France (GRID:grid.5613.1)
6 Georges François Leclerc Cancer Center—UNICANCER, Platform of Transfer in Biological Oncology, Dijon, France (GRID:grid.5613.1); University of Burgundy-Franche Comté, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313)
7 Georges François Leclerc Cancer Center—UNICANCER, Platform of Transfer in Biological Oncology, Dijon, France (GRID:grid.460771.3); Dijon University Hospital, Genomic and Immunotherapy Medical Institute, Dijon, France (GRID:grid.31151.37); University of Burgundy-Franche Comté, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313); UMR INSERM 1231, Dijon, France (GRID:grid.5613.1); Georges François Leclerc Cancer Center—UNICANCER, Department of Medical Oncology, Dijon, France (GRID:grid.5613.1)